July 23, 2024 12:18 PM EDTUpdated 02:54 PM
R&D
Pharma

Up­dat­ed: Mer­ck, with­out shar­ing de­tails, says RSV an­ti­body suc­cess­ful­ly pro­tect­ed in­fants

Max Bayer

Pharma Reporter

Mer­ck’s mon­o­clon­al an­ti­body to pro­tect in­fants from RSV hit its goals in a Phase 2b/3 tri­al, putting the US drug­mak­er a step clos­er to com­pet­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times